Wellington Management Group LLP Invests $138.75 Million in Definium Therapeutics, Inc. $DFTX

Wellington Management Group LLP bought a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 2,949,734 shares of the company’s stock, valued at approximately $138,755,000.

Several other institutional investors have also recently added to or reduced their stakes in DFTX. Bank of New York Mellon Corp boosted its position in Definium Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock valued at $36,563,000 after buying an additional 24,349 shares in the last quarter. Creative Planning increased its holdings in shares of Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after buying an additional 1,655 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Definium Therapeutics by 10.4% during the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after buying an additional 6,148 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Definium Therapeutics in the third quarter valued at approximately $379,000. Finally, Blair William & Co. IL raised its stake in shares of Definium Therapeutics by 43.6% in the third quarter. Blair William & Co. IL now owns 31,905 shares of the company’s stock valued at $376,000 after acquiring an additional 9,687 shares during the last quarter. 27.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Bank of America assumed coverage on Definium Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $75.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $70.00 price target on shares of Definium Therapeutics in a report on Wednesday, August 12th. Royal Bank Of Canada lifted their price objective on Definium Therapeutics from $57.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Maxim Group set a $55.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 14th. Finally, Needham & Company LLC increased their target price on Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $63.00.

Insider Transactions at Definium Therapeutics

In other news, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the sale, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 48,096 shares of company stock worth $2,165,763 in the last quarter. 2.40% of the stock is owned by corporate insiders.

Definium Therapeutics Price Performance

Shares of DFTX stock opened at $39.72 on Tuesday. Definium Therapeutics, Inc. has a 1 year low of $8.70 and a 1 year high of $49.70. The firm’s 50 day moving average is $43.99 and its 200-day moving average is $28.96. The firm has a market capitalization of $5.34 billion, a price-to-earnings ratio of -11.58 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Sell-side analysts forecast that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.